A carregar...
BiDil: Assessing a Race-Based Pharmaceutical
Isosorbide and hydralazine in a fixed-dose combination (BiDil) has provoked controversy as the first drug approved by the Food and Drug Administration marketed for a single racial-ethnic group, African Americans, in the treatment of congestive heart failure. Family physicians will be better prepared...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Copyright 2006 Annals of Family Medicine, Inc.
2006
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1687161/ https://ncbi.nlm.nih.gov/pubmed/17148635 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1370/afm.582 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|